APOA5 — Triglyceride Metabolism
APOA5 (Apolipoprotein A5) plays a key role in regulating triglyceride
levels. Discovered in 2001 | Pennacchio et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science, 2001 through comparative sequencing of the
APOA1/C3/A4 gene cluster, APOA5 was found to strongly influence plasma
triglyceride concentrations in both humans and mice.
The Mechanism
The S19W variant (rs3135506) causes a serine-to-tryptophan substitution at
position 19 (p.Ser19Trp) in the signal peptide| The signal peptide is a short amino-acid sequence that directs a newly made protein for secretion out of the cell of the APOA5 protein.
This disrupts the signal peptide function, reducing APOA5 secretion into
the bloodstream by approximately 50%. Since APOA5 normally lowers
triglycerides by stimulating lipoprotein lipase activity and inhibiting
VLDL production, reduced secretion leads to higher triglyceride levels.
The Evidence
The ICARIA study | Loria et al. Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia. BMC Med Genet, 2010 demonstrated that
APOA5 S19W carriers have an independent, additive triglyceride-raising
effect. Carriers of the rare allele show significantly higher levels of
large VLDLs (+133%) and small dense LDLs (+34%), creating a proatherogenic
lipid profile.
Guardiola et al. | Guardiola et al. APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis. Atherosclerosis, 2015 confirmed
that this variant predisposes carriers to atherogenic dyslipidemia and
subclinical atherosclerosis — measurable thickening of artery walls even
before symptoms appear.
High triglycerides are an independent risk factor for cardiovascular
disease and pancreatitis| Very high triglycerides (above roughly 500 mg/dL) can trigger acute pancreatitis, a serious inflammation of the pancreas.
Practical Implications
The C allele is found in about 6% of Europeans and up to 14% of
Hispanics, but is rare (<2%) in East Asian and African populations.
Dietary interventions — especially limiting refined carbohydrates and
increasing omega-3 intake — are the primary management strategy.
Interactions
Triglyceride-raising effects are additive when combined with variants
in LPL and APOE genes. If you also carry APOE E4 (rs429358), your
overall cardiovascular risk is compounded.
All Genotypes
Normal triglyceride metabolism
You have normal APOA5 function, shared by about 88% of Europeans. Your triglyceride levels respond typically to diet and lifestyle.
One variant - higher triglyceride tendency
You carry one copy of the S19W variant, found in about 11% of Europeans. This reduces APOA5 secretion by approximately 50%, leading to higher triglyceride levels. Carriers show significantly higher levels of proatherogenic large VLDLs and small dense LDLs.
Two variants - significantly higher triglycerides
You have two copies of the S19W variant, a rare genotype (~1% of Europeans). You have a strong genetic tendency toward higher triglyceride levels due to severely reduced APOA5 secretion. This significantly increases your risk of cardiovascular disease and potentially pancreatitis with very high triglyceride levels.